Current topics in medicinal chemistry · 2026
The Janus Face of PROX1 in Cancer--Context-Dependent Functions and Therapeutic Implications.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Jiayi, Li Songqiang, Ma Jiayi, Liu Yupu, Li Tongtong, Zhou Gang, Yuan Chengfu
Аннотация
INTRODUCTION: PROX1 is a conserved transcription factor with context-dependent roles in cancer. This review evaluates its dual nature as both an oncogenic driver and a tumor suppressor.
METHODS: This review, which involved scanning of pertinent literature, describes and evaluates recent research on the biological functions and mechanisms of PROX1 in malignancies.
RESULTS: The functions of PROX1 in cancer are highly context-dependent. In gastric cancer, colorectal cancer, and glioma, PROX1 acts as an oncogenic driver. Conversely, in pancreatic ductal adenocarcinoma, it serves as a tumor suppressor. In hepatocellular carcinoma, breast cancer, thyroid carcinoma, and vascular tumors, PROX1 exhibits a dual role. Specifically, in different types of vascular tumors, the expression of PROX1 is more closely associated with the lymphatic endothelial phenotype. Although it also partially indicates a malignant phenotype, this association is not entirely consistent.
DISCUSSION: The functional switch of PROX1 is primarily governed by its subcellular localization and interaction with specific targets. Its significant heterogeneity across cancer stages necessitates the development of more precise, context-aware diagnostic and treatment protocols.
CONCLUSION: PROX1 is a multifaceted transcription factor, with both tumor-suppressive and oncogenic roles in diverse cancers. Its diverse functions underscore the necessity for a nuanced understanding of its mechanisms in different cancer types and suggest that PROX1 holds significant potential as a therapeutic target and prognostic biomarker. This provides new avenues for the prevention and treatment of tumor diseases in the future.
METHODS: This review, which involved scanning of pertinent literature, describes and evaluates recent research on the biological functions and mechanisms of PROX1 in malignancies.
RESULTS: The functions of PROX1 in cancer are highly context-dependent. In gastric cancer, colorectal cancer, and glioma, PROX1 acts as an oncogenic driver. Conversely, in pancreatic ductal adenocarcinoma, it serves as a tumor suppressor. In hepatocellular carcinoma, breast cancer, thyroid carcinoma, and vascular tumors, PROX1 exhibits a dual role. Specifically, in different types of vascular tumors, the expression of PROX1 is more closely associated with the lymphatic endothelial phenotype. Although it also partially indicates a malignant phenotype, this association is not entirely consistent.
DISCUSSION: The functional switch of PROX1 is primarily governed by its subcellular localization and interaction with specific targets. Its significant heterogeneity across cancer stages necessitates the development of more precise, context-aware diagnostic and treatment protocols.
CONCLUSION: PROX1 is a multifaceted transcription factor, with both tumor-suppressive and oncogenic roles in diverse cancers. Its diverse functions underscore the necessity for a nuanced understanding of its mechanisms in different cancer types and suggest that PROX1 holds significant potential as a therapeutic target and prognostic biomarker. This provides new avenues for the prevention and treatment of tumor diseases in the future.